Albireo reports topline results from phase 2 trial of elobixibat in nafld/nash

Albireo reports topline results from phase 2 trial of elobixibat in nafld/nash.albireo pharma inc - trial achieved primary endpoint.albireo pharma inc - company discontinuing further development.albireo pharma inc - trial showed unremarkable results in key nash measures.albireo pharma inc - trial did not achieve proof-of-concept for other key nash measures.
ALBO Ratings Summary
ALBO Quant Ranking